An observational study in Adult Congenital Heart Disease, Congenital Heart Disease and Systemic Right Ventricle, sponsored by Leiden University Medical Center. Recruiting at 11 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by Leiden University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Tetralogy of Fallot with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Tetralogy of Fallot · United States.
Among the 32 studies in Tetralogy of Fallot with a site in United States, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2023, is one of 12 observational ones, reaches primary completion later than 9 of the 11 other live ones, and was the 30th registered.
92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.
Browse Tetralogy of Fallot studies →7 of the 32 studies in Tetralogy of Fallot with a site in United States are open now. Recruiting first, the newest first:
Boston Children's Hospital · Sites in United States
Ages 1 days–17 yrs
PECA Labs · Sites in United States
Ages 0–22
Weill Medical College of Cornell University · Sites in United States
Ages 30 days–100 days
Mayo Clinic · Sites in United States
Ages 18+
Edwards Lifesciences · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 17 Tetralogy of Fallot studies recruiting now, 8 (47%) set no upper age limit and 9 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 150 across 40 observational studies indexed under Tetralogy of Fallot.
Median enrollment 35 across the 20 interventional studies, 152 across the 12 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 32 have an industry lead sponsor. The 10 most frequent:
Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.
Leiden University Medical Center has 1 study filed under Tetralogy of Fallot — fewer than ten, so there is no comparison to draw.
3 of the studies in Tetralogy of Fallot with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05077774Medtronic CardiovascularHarmony TPV Post-Approval Study | 2026-11 |
| NCT02744677Edwards LifesciencesCOMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | 2026-12 |
| NCT07184476Boston Children's HospitalAssessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient | 2027-03-17 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Tetralogy of Fallot with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
In the adult congenital heart disease (ACHD) population, heart failure currently represents the main cause of morbidity and mortality. The etiology of ACHD-related heart failure is heterogenous, and there is limited evidence for pharmacological treatment options for this population.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel pillar in the treatment of conventional LV heart failure. SGLT2i have been shown to reduce the risk of worsening heart failure and cardiovascular-related death in patients with LV heart failure.
While the exact mechanisms of action are still to be elucidated, SGLT2i seem to address heart failure by targeting several pathways. These include but are not limited to; a decrease in renin-angiotensin and sympathetic nervous system activation, a decrease in pressure overload-induced myocardial fibrosis, reverse cardiac remodeling, and improvement in myocardial energetics.
Given the compelling evidence on the effectiveness of SGLT2i over a broad range of cardiac dysfunction and initial promising reports of its utilization in the field of ACHD, SGLT2i deserve further exploration in the group of ACHD patients.
This real-world, international registry aims to evaluate the current experience with SGLT2i in ACHD patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Project design:
Data of all ACHD patients who were started on an SGLT2i will be collected in a real-world, international registry. Only data resulting from routine clinical care will be collected from the electronic health records at the participating centers, and participants will not undergo any interventions for this project. Data will be collected from 1 year before starting with the SGLT2i to most recent follow-up after starting with the SGLT2i, to evaluate if SGLT2i therapy halts the progression of clinical deterioration in ACHD patients with heart failure and can improve heart failure-related outcomes.
92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.
This study's planned enrollment of 400 is above the median of 150 across 40 observational studies indexed under Tetralogy of Fallot.
Browse Tetralogy of Fallot studies →Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.
Compared within Tetralogy of Fallot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Heart Defects, Congenital. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All adult patients (≥ 18 years) with congenital heart disease who have been treated with an SGLT2i are eligible for inclusion in the registry.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- No consent for data collection.
All participants included in the registry have to have a congenital heart defect, be ≥ 18 years old, and receive (or have received) treatment with SGLT2i.
Drug: SGLT2 inhibitors
Treatment with any type and dose of sodium-glucose cotransporter 2 inhibitor.
Prescription patterns
The primary outcome of this registry is an overview of the prescription patterns of SGLT2i in the ACHD population.
Time frame: Baseline information.
Side effects [Safety and Tolerability]
Incidence and specification of any experienced side effects.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
SGLT2i-related complications [Safety and Tolerability]
Incidence and specification of any SGLT2i-related complications.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
SGLT2i discontinuation [Safety and Tolerability]
Incidence of any discontinuation of SGLT2i (including reason for discontinuation).
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Mortality [Safety and Tolerability]
Mortality and documentation of cause of death.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Admissions [Heart Failure-related Efficacy]
Documentation of number of hospitalizations, including number of heart failure-related hospitalizations and number of urgent heart failure visits.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Clinical parameters - weight [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on weight (kg)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Clinical parameters - systolic blood pressure [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on systolic blood pressure (mmHg)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Clinical parameters - diastolic blood pressure [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on diastolic blood pressure (mmHg)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Clinical parameters - heart rate [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on heart rate (beats per minute)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Clinical parameters - saturation [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on oxygen saturation (%)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - sodium [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum sodium (mmol/L)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - potassium [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum potassium (mmol/L)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - creatinine [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum creatinine (µmol/L)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - eGFR [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on estimated glomerular filtration rate (eGFR, ml/min/1.73m2)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - NT-proBNP [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum NT-proBNP (ng/L)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - glucose [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum glucose (mmol/L)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Laboratory parameters - HbA1c [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on serum HbA1c (mmol/mol Hb)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - LV function [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on systolic left ventricular (LV) function (categorical: good, mildly reduced, moderately reduced, severely reduced function)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - LV GLS [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on LV global longitudinal strain (GLS, %) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - LV FAC [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on LV fractional area change (FAC, %) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - RV function [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on systolic right ventricular (RV) function (categorical: good, mildly reduced, moderately reduced, severely reduced function) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - RV GLS [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on RV GLS (%) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - RV FAC [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on RV FAC (%) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - RV S' [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on RV S' (cm/s) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Transthoracic echocardiography - TAPSE [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on tricuspid annular plane systolic excursion (TAPSE, mm) assessed with transthoracic echocardiography
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Exercise parameters - 6MWT [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on exercise parameter 6-minute walk test (6MWT, meters)
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Exercise parameters - maximum performance [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on maximum performance (Watt) with bicycle ergometry.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Exercise parameters - validity [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on validity (%-predicted of the maximum performance) with bicycle ergometry.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Exercise parameters - VO2 max [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on VO2 max (mL/kg/min) with bicycle ergometry.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Exercise parameters - %-predicted VO2 max [Heart Failure-related Efficacy]
Evaluation of the longitudinal effect of SGLT2i on %-predicted of VO2 max (% of the VO2 max) with bicycle ergometry.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Concomitant medication changes [Heart Failure-related Efficacy]
Evaluation of the concomitant changes in other heart failure pharmacotherapy.
Time frame: From enrollment through study completion, with an average follow-up duration of 1 year.
Started Jan 2023 (actual). Primary completion is estimated for Dec 2027, 59 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leiden University Medical Center →